Labcorp
Provides clinical diagnostics and global laboratory support for biopharma research.
Something off on this page? Send us feedback.
Profile
Sells routine and specialty diagnostics to healthcare providers, payers, employers, and patients, while providing central-laboratory and early-development services to biopharma customers. Most revenue comes from U.S. diagnostics, complemented by a global drug-development laboratory network.
Provides routine and specialty clinical testing through Diagnostics Laboratories, including anatomic pathology, genetics, genomics, toxicology, and consumer-initiated tests. Collection sites, specimen logistics, automated processing, and digital delivery serve physicians, health systems, payers, employers, and patients; nearly all segment revenue comes from the United States.
Supports drug development through Biopharma Laboratory Services. Its Central Laboratory and Early Development Research Laboratories businesses provide trial testing, kits, sample logistics and management, bioanalysis, and safety assessment for pharmaceutical, biotechnology, diagnostic, and contract-research customers across the United States, Europe, and Asia.
Links a broad test menu with collection access, laboratory automation, health-system partnerships, and global trial logistics. Revenue depends on testing volumes, biopharma research activity, payer contracts and reimbursement, and compliance with laboratory, billing, privacy, and drug-development regulations.
Company facts
Key statistics
Year to date +33.2% · Average volume (30d) 724.0K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 10, 2026 | Mizuho Securities | Target | $320 | $355 | |
| Jul 31, 2026 | Morgan Stanley | Reiterate | Overweight | $303 | $338 |
| Jul 31, 2026 | Deutsche Bank | Reiterate | Hold | $265 | $306 |
| Jul 31, 2026 | Robert W. Baird | Target | $334 | $352 | |
| Jul 30, 2026 | Barclays | Target | $290 | $320 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026Q2 FY26 | $4.78 | $4.99 | +4.4% | $3.71B | $3.73B | +0.6% | +2.73% |
| Apr 30, 2026Q1 FY26 | $4.11 | $4.25 | +3.4% | $3.51B | $3.54B | +0.8% | −0.37% |
| Feb 17, 2026Q4 FY25 | $3.95 | $4.07 | +3.0% | $3.56B | $3.52B | −1.2% | +0.76% |
| Oct 28, 2025Q3 FY25 | $4.13 | $4.18 | +1.2% | $3.56B | $3.56B | +0.2% | −4.45% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $3.35B | $3.53B | $3.56B | $3.52B | $3.54B | $3.73B | |
| Gross profit | $948.0M | $1.05B | $1.03B | $920.6M | $938.2M | $1.11B | |
| Operating income | $326.0M | $394.5M | $396.6M | $382.0M | $387.2M | $451.6M | |
| Net income | $212.8M | $237.9M | $261.1M | $164.7M | $277.8M | $298.7M | |
| Diluted EPS | $2.52 | $2.84 | $3.12 | $1.98 | $3.35 | $3.64 | |
| Gross margin | 28.3% | 29.7% | 28.8% | 26.2% | 26.5% | 29.8% | |
| Operating margin | 9.7% | 11.2% | 11.1% | 10.9% | 10.9% | 12.1% |
Fiscal years (4-quarter sums)FY21 $16.12B · FY22 $13.36B · FY23 $12.16B · FY24 $13.01B · FY25 $13.95B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $141.8M · Total debt $6.77B · Total assets $18.53B · Shareholders' equity $8.61B
Dividends
Raised for 3 straight years — most recently to $0.72 from $0.6186 split-adjusted in Aug 2023. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Aug 28, 2026 | Aug 28 | Sep 11 | $0.72 | |
| May 29, 2026 | May 29 | Jun 11 | $0.72 | |
| Feb 27, 2026 | Feb 27 | Mar 12 | $0.72 | |
| Nov 26, 2025 | Nov 26 | Dec 11 | $0.72 | |
| Aug 28, 2025 | Aug 28 | Sep 11 | $0.72 | |
| May 29, 2025 | May 29 | Jun 11 | $0.72 | |
| Feb 27, 2025 | Feb 27 | Mar 12 | $0.72 | |
| Nov 26, 2024 | Nov 26 | Dec 13 | $0.72 |
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 82.00M · Float 81.67M · 99.6% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 6.57M | 8.02% | 13F | Aug 7, 2026 |
| Vanguard Capital Management LLC | 5.36M | 6.54% | 13F | Aug 13, 2026 |
| Victory Capital Management Inc | 4.84M | 5.90% | 13F | Aug 7, 2026 |
| State Street Corp | 3.91M | 4.77% | 13F | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 3.68M | 4.49% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 17, 2026 | Kerrii B. Anderson | director | −3,000 | $318.02 |
| Aug 11, 2026 | Adam H. Schechter | director, officer: President & CEO | −4,669 | $320.37 |
| Aug 4, 2026 | Amy B. Summy | officer: EVP, Chief Marketing Officer | −924 | $306.74 |
| Aug 3, 2026 | Peter J. Wilkinson | officer: SVP, Chief Accounting Officer | −1,420 | $309.23 |
| Jul 2, 2026 | Bryan T. Vaughn | officer: EVP and President, Diagnostics | −234 | $286.19 |
Peers
- Quest Diagnostics
Closest national overlap in diagnostic information services
- Thermo Fisher Scientific
Pharma-services and PPD overlap in biopharma labs
- IQVIA
Global clinical research and central-lab overlap
- ICON
Central-lab and CRO overlap for trial sponsors
- NeoGenomics
Oncology diagnostics and pharma-services overlap
- Charles River Laboratories
Early-development and safety-assessment overlap
- Medpace
Smaller CRO central-lab overlap in clinical trials
- OPKO Health
Narrow BioReference overlap after asset sales
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Labcorp | $333.00 | −0.68% | $27.48B | 27.7 | 17.7 | 1.9 | +5.8% |
| Quest Diagnostics | $244.50 | +0.69% | $26.79B | 25.8 | 21.2 | 2.3 | +10.2% |
| Thermo Fisher Scientific | $620.01 | −0.32% | $231.22B | 33.5 | 23.7 | 5.0 | +10.5% |
| IQVIA | $261.75 | +0.03% | $43.08B | 32.5 | 19.2 | 2.5 | +8.7% |
| ICON | $170.02 | +0.07% | $13.02B | 39.9 | 15.2 | 1.6 | +2.3% |
| NeoGenomics | $18.20 | +0.86% | $463.8M | — | 64.9 | 0.6 | +11.2% |
| Charles River Laboratories | $291.50 | +0.04% | $14.04B | — | 23.7 | 3.5 | −2.7% |
| Medpace | $600.65 | +0.03% | $16.77B | 35.2 | 32.7 | 6.0 | +17.2% |
| OPKO Health | $1.46 | −1.68% | $1.10B | — | — | 1.9 | +4.3% |
| Median | 33.5 | 23.7 | 2.4 | +9.5% |